TP53 and breast carcinoma: Our experiments show that T-oligos are effective against p16-null MCF-7 breast cancer cells as well as adriamycin-resistant P-glycoprotein-expressing cells that additionally have non-functional p53, suggesting that T-oligos may be effective against at least some chemotherapy-resistant tumors.